blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

What is precision patient finding?

Precision patient finding is an evolving field that is growing in line with the demands of precision medicine and rare disease research. Unlike traditional patient recruitment methods, it harnesses technologies such as data analysis and advanced analytics, and utilizes comprehensive patient data (including genomic profiles) to rapidly identify groups of patients who have an increased likelihood of study eligibility and enrollment. Here we’ll explore some of the key elements of precision patient finding and how they interlink.

Continue reading

Overcoming challenges in precision neurology

Implementing precision neurology comes with its own set of complexities—from decoding the brain's intricate workings to addressing the ethical challenges of using genetic data. Let’s take a closer look at these hurdles.

Continue reading

Podcast recap: Dr. Jim Wilson on the genetics of isolated communities

In the latest episode of The Genetics Podcast, Patrick speaks with Dr. Jim Wilson, Professor of Human Genetics at the University of Edinburgh, about his work studying isolated populations and their unique genetic makeup. As the lead of the Viking Genes project, Jim's research explores the genetic history of Scottish islanders. They have already found several genetic variants of interest, including a BRCA1 mutation present in 1 in 20 individuals on one island, and a cardiomyopathy variant 4,700 times more common in Shetland. Discoveries like these have profound implications for population health and preventive medicine. Read on for a quick summary of the episode:

Continue reading

Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease

Sano is proud to support Neuron23 in the NEULARK Phase 2 clinical trial, a groundbreaking study exploring NEU-411, a brain-penetrant LRRK2 inhibitor with the potential to slow disease progression in Parkinson’s. This precision medicine trial leverages advanced digital biomarkers and patient stratification techniques to identify those most likely to benefit from treatment.

Continue reading

Podcast recap: Michelle Teng on transforming immunotherapy with machine learning

Last week on The Genetics Podcast, Patrick Short sat down with Michelle Teng, CEO and co-founder of Etcembly, to explore her work at the intersection of immunotherapy and machine learning. The discussion ranged from breakthroughs in cancer treatment to Michelle’s deeply personal motivation for advancing rare disease therapies. In case you missed it, here's a quick recap of the episode:

Continue reading

What’s driving progress in precision neurology?

Precision medicine is transforming neurology by enabling more accurate diagnoses and tailored treatments. Here, we explore key components driving this progress, including biomarkers, advances in genomic sequencing, and other critical areas of research.

Continue reading

Podcast recap: Eric Fauman on leveraging genetic data for drug discovery at Pfizer

In a recent episode of The Genetics Podcast, host Patrick Short sits down with Eric Fauman, Executive Director and Head of Computational Biology in Pfizer's Internal Medicine Research Unit. With over 26 years at Pfizer and a background in protein crystallography and genetics, Eric's work combines computational biology and genetics to drive drug discovery, particularly through the development of tools and datasets that bring genetic insights into the drug development process.

Continue reading

How precision medicine is transforming neurological health care

Millions of people worldwide are affected by neurological disorders like ALS, Alzheimer’s, and Parkinson’s. These conditions bring unique challenges for patients and healthcare providers, but precision medicine is helping change how we approach them. By focusing on the genetic and molecular causes of these diseases, precision neurology is opening the door to more effective, personalized care.

Continue reading

Podcast recap: Building Noga Therapeutics and advancing gene therapy for rare diseases with Noam Baumatz

In the most recent episode of The Genetics Podcast, host Patrick Short speaks with Noam Baumatz, co-founder and CEO of Noga Therapeutics. Noam shares his deeply personal journey into gene therapy and the mission behind Noga Therapeutics, a company focused on developing gene therapies for rare genetic disorders. The conversation explores Noam’s work, the powerful motivation behind it, and how it supports families through rare diseases.

Continue reading

Lupus Research Alliance Launches the DREAM Knowledge-Exchange Platform to Accelerate Precision Medicine in Lupus

Today, the Lupus Research Alliance (LRA) launched the Data Repository, Exchange, and Analytics Platform (DREAM)—a pioneering knowledge-sharing platform dedicated to advancing lupus research. DREAM offers two interfaces: one designed for secure data-sharing and collaboration among researchers, and another focused on research engagement for individuals living with lupus.

Continue reading

Innovating for impact: How natural history studies pave the way for rare disease therapies [webinar recap]

In a recent webinar, former Reata Pharmaceuticals CEO Warren Huff shared his journey leading the company from its founding in 2002 to its landmark acquisition by Biogen in 2023. Warren offered an in-depth look into Reata’s development of Skyclarys, the first FDA-approved treatment for Friedrich’s ataxia, a rare neurodegenerative disease that dramatically affects patients’ quality and length of life. Below is a quick summary of the key bits of info from the webinar.

Continue reading

Exploring inherited retinal disorders (IRDs): Causes, challenges, and future treatments [report]

Inherited retinal disorders (IRDs) are a diverse group of genetic eye conditions that impact millions worldwide, affecting light-sensitive cells in the retina and leading to vision impairment. Our latest report, "Inherited retinal Disorders: A primer," explores these conditions, their prevalence, the genetics behind them, and current treatment options.

Continue reading

Podcast recap: Q3 insights with Dr. Veera Rajagopal

In the latest episode of The Genetics Podcast, Patrick welcomes back Dr. Veera Rajagopal, a drug discovery scientist at Regeneron, for his quarterly discussion about the latest breakthroughs in genetic research. Together, they take a close look at some of the most exciting papers from the past few months, focusing on evolutionary genetics, structural variants, and new research into disease mechanisms.

Continue reading

Challenges in developing new therapies for Inherited Retinal Disorders (IRD)

Inherited retinal diseases (IRDs) are a leading cause of genetic vision loss, yet they remain difficult to identify and diagnose. Genetic testing plays a pivotal role in identifying the underlying causes, opening the door to timely treatment and improved patient outcomes. Here, we explore key barriers to diagnosing IRDs and the importance of early genetic screening in managing these rare conditions.

Continue reading

Sano Genetics named in Bloomberg UK’s Startups to Watch 2024

LONDON – 22 October 2024: Sano Genetics, the UK-based precision medicine company accelerating precision medicine clinical trials, has been named as one of Bloomberg’s Startups to Watch 2024. This latest recognition highlights the business’s significant growth and impact improving access to clinical trials and precision medicine. 

Continue reading

Eyeing the future: Genetic insights driving personalized eye care

Over 350 hereditary eye conditions are currently known, collectively affecting around one in every 1,000 people globally. These genetic disorders can influence various parts of the eye, such as the cornea, lens, retina, and optic nerve. Though they differ in their symptoms and severity, they all face a shared challenge: the critical need for early, precise diagnosis and tailored treatments.

Continue reading

Podcast recap: Bridging genomics, business, and equity in healthcare access with Mark Taylor

In the latest episode of The Genetics Podcast, host Patrick Short interviews Mark Taylor, Head of Strategic Partnerships at the National Institute for Health and Care Research (NIHR) in the UK. During their conversation, Mark offers insights from his dual perspective as a leader in health research and as someone living with multiple sclerosis (MS). They discuss advancements in healthcare, the barriers to introducing new technologies into the National Health Service (NHS), and how engaging with underrepresented communities will shape the future of medical research.

Continue reading

Seeing the future: Breakthroughs in genetic eye disease diagnosis and therapy [Whitepaper]

Genetic eye diseases present significant challenges for patients and healthcare providers alike. Conditions like retinitis pigmentosa, Stargardt disease, and Leber Congenital Amaurosis (LCA) can lead to progressive vision loss, but with ongoing advancements in genetic research, there is growing hope for earlier diagnosis and more targeted therapies.

Continue reading

New partnership to boost access to specialist eye care and related research for patients across the USA

A new partnership announced today will offer seamless, end-to-end solutions that will drive progress in both patient care and research outcomes in inherited retinal diseases (IRD). 

Continue reading

Genetic risk factors for chronic kidney disease and their role in precision medicine

Chronic Kidney Disease (CKD) is a major health concern that impacts millions of people worldwide. While there are environmental and lifestyle factors that increase a person's risk of developing the condition, like smoking or obesity, there are also several genes like APOL1, PKD1, and PKD2, that have been shown to significantly influence CKD risk and progression. Understanding these genetic risk factors opens the door for precision medicine, offering faster diagnoses and more effective treatments for CKD patients.

Continue reading

Podcast recap: Exploring the future of AAV gene therapy with Paul Wille

In the latest episode of the Genetics Podcast, host Patrick Short spoke with Paul Wille, Director of Product Development at Abeona Therapeutics, about adeno-associated virus (AAV) in gene therapy. The conversation covered the advantages of AAV as a gene delivery vehicle, the challenges slowing down its uptake, and its potential uses, particularly in eye conditions. Here’s a breakdown of the key points from their discussion:

Continue reading

Webinar recap: Precision medicine ethics: Navigating genetic screening with care

In a recent webinar hosted by Lindsey Wahlstrom-Edwards, Partnerships Lead at Sano Genetics, expert speakers explored the complexities of genetic testing and its ethical considerations, particularly in relation to patient care, public health programs, and data privacy. What follows is a recap on “Precision medicine ethics: Navigating genetic screening with care.”

Continue reading

Podcast recap: Exploring the future of health monitoring with Dr. Mike Snyder

On last week's episode of The Genetics Podcast, host Patrick Short was joined by Dr. Mike Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University. Known for his work in multiomics and personalized health monitoring, Dr. Snyder shares his career journey and discusses his unique approach of using himself as the first participant in his own studies. Their conversation covers everything from the future of healthcare to the potential of wearables and multiomics data in predicting illness before symptoms show.

Continue reading

Precision medicine around the world [report]

Precision medicine is paving the way for better healthcare by providing hope for more personalized and effective treatments for patients. But how is this approach evolving around the world? Our latest report, Mapping the precision medicine landscape: Regional insights and future horizons, takes a deep dive into how precision medicine is shaping healthcare systems across North America, Asia Pacific, Europe, Africa, and Latin America.

Continue reading

Why does precision medicine matter?

Precision medicine is reshaping healthcare by moving away from a one-size-fits-all approach to more personalized care. By understanding each patient's genetic makeup, environment, and lifestyle, healthcare professionals can develop targeted treatment and prevention strategies. In this blog, we’ll explore how this approach is making treatments more effective, identifying at-risk individuals, and potentially reducing healthcare costs while addressing key challenges along the way.

Continue reading

Podcast recap: How genomics is rewriting the taxonomy of disease with Dr. Lon Cardon

In the latest episode of The Genetics Podcast, host Patrick Short welcomes Dr. Lon Cardon, CEO of the Jackson Laboratory, to discuss his career journey, the rise of genome-wide association studies (GWAS), the shift from candidate gene studies, and the future of drug discovery in both rare and common diseases. With a career spanning academia, industry, and now leading one of the most iconic genetics research institutions, Lon shares his insights into how the field of genetics has evolved and what lies ahead.

Continue reading

The internationalization of precision medicine: Challenges of implementation

While precision medicine holds great promise for both patients and the growth of global markets, there are significant obstacles to be overcome to enable its widespread adoption in a context which ensures equality of access. In this blog, we’ll explore how mind-bending volumes of data, a lack of trained specialists, and the huge costs of drug development all pose challenges which must be addressed to ensure successful implementation of precision medicine strategies internationally.

Continue reading

Emerging trends and future research areas in aging and longevity

As the global population ages, understanding the genetic, biological, social, and environmental factors influencing longevity has become a key area of research. Advances in genetics are helping researchers unravel how our genes interact with lifestyle and environmental factors to influence not only how long we live but also how healthily we age. Here, we examine genetic research areas that could shape the future of aging and longevity.

Continue reading

Podcast recap: Uncovering the secrets of gene regulation with Nadav Ahituv

In the latest episode of The Genetics Podcast, host Patrick Short welcomes Nadav Ahituv, Director of the Institute for Human Genetics at the University of California San Francisco (UCSF). Together, they discuss the complex world of gene regulation, covering everything from non-coding DNA to advances in genetic technologies. Nadav shares his research on how gene regulatory elements influence human evolution, disease, and diversity, as well as the cutting-edge methods his lab is using to explore these elements.

Continue reading

Global market expansion and the future of precision medicine: The case for internationalization [whitepaper]

Breakthrough technologies and data innovation are driving cost reductions and increasing return on investment in precision medicine, fueling accelerated international market growth. With the sector poised for rapid expansion—the market is projected to reach $50.2 billion by 2028—innovators must adopt a global mindset to tackle the challenges of managing and processing data at an unprecedented scale. Addressing the shortage of trained specialists and confronting emerging ethical challenges will also be critical to unlocking the full potential of the precision medicine market and delivering for patients.

Continue reading

Podcast recap: Understanding cell aging and its role in disease with Marco Quarta

In this episode of The Genetics Podcast, host Patrick Short sits down with Marco Quarta, Co-founder and CEO of Rubedo Life Sciences, to discuss the biology of aging and the innovative work his company is doing to address age-related diseases. They discuss cellular senescence (a biological process where cells stop dividing but remain alive), the challenges of understanding aging at the molecular level, and Rubedo’s unique approach to developing therapeutics targeting aging cells.

Continue reading

What are the key genetic and epigenetic determinants of longevity?

Longevity – length of life – is influenced by a complex interplay of genetic, environmental, and epigenetic factors. As the global population ages, understanding the determinants of longevity has become a central focus in the fields of genetics and precision medicine. We’ve recently been having some very interesting discussions around aging on The Genetics Podcast – so here, we explore the key genetic and epigenetic factors that contribute to human lifespan and highlight their potential impact on health outcomes as we age.

Continue reading

Podcast recap: Exploring aging research with Martin Borch Jensen of Gordian Biotechnology

In this episode of The Genetics Podcast, host Patrick Short talks with Martin Borch Jensen, Co-founder and Chief Scientific Officer at Gordian Biotechnology, about his journey into the biology of aging and the innovative approaches his company is using to tackle age-related diseases. They discuss the science behind aging, intermittent fasting, and Gordian's cutting-edge tools for drug development.

Continue reading

Building the future of public health with genetic screening [report]

Genetic screening is poised to significantly enhance public health by improving the way we detect, prevent, and manage diseases. However, successfully integrating genetic screening into public health systems requires strategic planning across several key areas. Our report, "Strategic pathways for integrating genetic screening into public health," outlines the essential steps needed, focusing on infrastructure development, policy, and international collaboration.

Continue reading

Podcast recap: Navigating genomics during the pandemic with Dr. Tony Cox

In the latest episode of The Genetics Podcast, host Patrick Short welcomes Dr. Tony Cox, CEO of the UK Biocentre, to discuss his 20 years of experience at the Wellcome Sanger Institute. Dr. Cox also shares his journey from joining the UK Biocentre at the onset of the COVID-19 pandemic to leading one of the UK's Lighthouse Labs, a role for which he was awarded an Officer of the Order of the British Empire (OBE).

Continue reading

Seeing the unseen: How genetic testing predicts and prevents disease

Genetic sequencing has significantly advanced our ability to detect individuals at increased risk of developing specific conditions and to identify diseases in their earliest stages. Predictive genetic testing can reveal susceptibilities to conditions like cancer, while diagnostic testing enables the detection of diseases before symptoms arise. These tools offer the potential for more personalized and effective healthcare. However, with these advancements come important considerations around accessibility, ethics, and practical implementation. This blog will explore how genetic testing is shaping the future of early disease detection and the essential need for equitable access to these critical technologies.

Continue reading

Podcast recap: Exploring the Million Veterans Program with Dr. Mike Gaziano

In the latest episode of The Genetics Podcast, host and Sano CEO Patrick Short explores population genomics and precision medicine with Dr. Mike Gaziano. Dr. Gaziano is a Professor of Medicine at Harvard, working at VA Boston and Brigham and Women's Hospital. He is one of the two principal investigators of the Million Veterans Program (MVP), the largest health system-based mega biobank in the world.

Continue reading

The importance of genetic testing as a public health initiative [whitepaper]

Decreasing costs, improved technologies, and increased prevalence of chronic and infectious disease are driving an explosion in the use of genetic testing across research, clinical trials, and public health. Healthcare is on the cusp of an unprecedented opportunity to integrate sequencing as a core initiative which not only improves individual patient outcomes and population-scale research, but reduces burden on stressed health systems and opens the door to international collaboration on an unparalleled scale. 

Continue reading

Podcast recap: Exploring the future of personalized medicine with Dr. Scott Weiss

In the latest episode of The Genetics Podcast, host and Sano Genetics CEO Patrick Short explores the evolving landscape of personalized medicine with Dr. Scott Weiss, a Professor of Medicine at Harvard Medical School and Associate Director of the Channing Division of Network Medicine (CDNM) at Brigham and Women's Hospital (BWH).

Continue reading

Policy-driven economic impacts of precision medicine

The integration of precision medicine into healthcare systems presents significant economic opportunities. By focusing on tailored treatments, precision medicine not only promises improved patient outcomes but also drives cost savings and efficiency across the healthcare sector. In this blog, we explore the economic impacts of precision medicine and the necessity of supportive policy measures to fully harness its benefits. This strategy not only fosters economic growth but also improves patient care and enhances the efficiency of the overall healthcare system.

Continue reading

20 clinical trial patient recruitment companies to drive your research forward, and how to choose one

Medical research is moving faster than ever, and while this is exciting news for patients waiting for new and better treatments, it also highlights the bottlenecks that are slowing the process down. One such bottleneck is clinical trial patient recruitment; a third of all delays for Phase III studies are caused by difficulties finding patients to take part. And while it’s estimated that recruitment costs make up 40% of all trial expenditures, 80% of studies fail to meet their enrollment deadlines. These delays are costly, too – for many sponsors, every month delayed can cost an additional $1 million

Continue reading

Pioneering personalized healthcare [infographic]

Despite being in the early stages, AI's integration into genomics has already created a wave of change in many aspects of healthcare.

Continue reading

Podcast recap: The biology of aging with Dr. Austin Argentieri

In the latest episode of The Genetics Podcast, host and Sano Genetics CEO Patrick Short explores the world of aging research with Dr. Austin Argentieri. Dr. Argentieri is a research fellow at Harvard and the Broad Institute, working in the Analytical and Translational Genetics Unit at Massachusetts General Hospital. With a background that includes a PhD and postdoc from the Big Data Institute at the University of Oxford, Dr. Argentieri focuses on large-scale analyses to understand the genetic, biological, and environmental determinants of human aging and aging-related diseases.

Continue reading

Challenges and ethical considerations of AI in precision medicine

While AI can be incredibly helpful in interpreting complex genomic data and predicting patient outcomes, using it within healthcare is not without challenges and raises important ethical considerations as well. Here, we'll outline some of these important issues:

Continue reading

Podcast recap: Navigating rare disease drug development regulations with Daniel O'Connor

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short sat down with Daniel O’Connor, an expert in regulatory policy for innovative medicines, particularly those focused on rare diseases. Daniel, who spent nearly 20 years at the MHRA (Medicines and Healthcare products Regulatory Agency) and recently joined the ABPI (Association of the British Pharmaceutical Industry), shared his extensive experience and insights into the regulatory landscape of rare disease drug development.

Continue reading

Partnering for progress: The Lupus Nexus Initiative with Lupus Research Alliance

At Sano, we are constantly exploring new ways to use our technology expertise to make a meaningful impact on healthcare. That’s why we’re excited about our partnership with the Lupus Research Alliance (LRA) on a profoundly important project: the Lupus Nexus initiative. This collaboration represents a significant step forward in our efforts to contribute to critical advancements in the field of lupus research.

Continue reading

Analyzing genomic data with AI

The progress in genome sequencing has catalyzed a significant transformation in the field of digital biology. Genomics programs across the world are gaining momentum as the cost of high-throughput, next-generation sequencing has dropped dramatically over the past decade. Now, whole genome sequencing is becoming a fundamental step in clinical workflows and drug discovery, especially for critical-care patients with rare diseases and in population-scale genetics research. However, traditional methods for analyzing genomic data are facing challenges in coping with the explosion of bioinformatics data.

Continue reading

Podcast recap: Q2 insights with Dr. Veera Rajagopal

In the most recent episode of The Genetics Podcast, Sano CEO Dr. Patrick Short explored the latest discoveries in genetics and precision medicine with returning guest Dr. Veera Rajagopal. Dr. Veera, a scientist at Regeneron and quarterly guest on our podcast, provided insights into recent influential studies reshaping our understanding of genetic disorders and their implications for medical treatment.

Continue reading

Predicting patient outcomes through AI

Predicting how a patient will react to medication or treatment involves understanding many factors, including their genetic makeup. Each patient's genome can hold clues about how they might respond to certain drugs, their risk of adverse drug reactions, or their susceptibility to particular diseases. However, the sheer volume and complexity of genomic data make it challenging for traditional analysis methods to efficiently process and interpret this information.

Continue reading

Podcast recap: Harnessing human data in drug development with Jakob Steinfeldt

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short sat down with Jakob Steinfeldt, co-founder and Chief Scientific Officer at Pheiron. Jakob shared his journey from academia to entrepreneurship and the innovative work Pheiron is doing in disease prediction and drug development.

Continue reading

Webinar recap: Sano’s patient finding protocol: Helping you find the right patients faster

In a recent webinar, Hayley Holt, Senior Programme Manager at Sano Genetics, provided an insightful discussion on Sano's innovative approach to patient finding, starting with the development of a patient finding protocol.

Continue reading

An overview of AI in genomics

AI's significance in genomics lies in its ability to uncover hidden patterns, provide diagnostic insights, and enhance our understanding of genetic information. The reason AI can be so helpful in genetics is that the complexity and sheer volume of genomic data poses significant challenges to traditional methods, which struggle to efficiently analyse and interpret this information. AI addresses this hurdle by offering computational tools capable of handling, extracting, and deciphering valuable insights from a huge amount of data.

Continue reading

Challenges and ethical considerations of integrating genetics into clinical practice

Integrating precision medicine into clinical practice offers immense benefits for patient care but also poses significant challenges and ethical considerations that need careful navigation in the coming years. Here's a summary of the key issues:

Continue reading

Podcast recap: From genome to bedside with Dr. Andrea Gropman

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had a fascinating discussion with Dr. Andrea Gropman, a distinguished expert in paediatric neurology, genetics, and inborn errors of metabolism. Dr. Gropman shared her extensive experience in the field and discussed the challenges and opportunities in integrating genetics and genomics into modern medical practice.

Continue reading

Podcast recap: Bringing genomics to the clinic with Lori Orlando

Last week on The Genetics Podcast, Sano CEO Patrick Short sat down with Lori Orlando, Director of the Precision Medicine Program at the Center for Applied Genomics and Precision Medicine at Duke University. Lori shared her journey from mathematical modelling to integrating family history and genetic data into primary care, discussing the impact of genomics on healthcare and the future of personalised medicine.

Continue reading

Integrating genetic data into clinical practice

The incorporation of genetics into contemporary clinical practice is essential for facilitating personalised treatment plans and early diagnosis, and can lead to significantly better patient outcomes. This guide provides healthcare providers with a comprehensive overview of how to effectively integrate genetic data into clinical settings. Here are some key points covered:

Continue reading

Genomic applications in frontline healthcare for at-risk populations

In terms of identifying and supporting at-risk populations, genomics has multiple potential applications in frontline healthcare. While confirmation of an underlying genetic factor can’t currently change patient outcomes, it’s hoped that collecting genomic data will enable families to quickly identify members at increased risk, and ultimately accelerate the development of potential new drug targets and personalised treatment journeys.

Continue reading

Policies, legislative proposals, and collaborative efforts driving precision medicine

The advancement of precision medicine hinges on supportive policies, legislative frameworks, and collaborative efforts that foster innovation, streamline regulatory processes, and ensure equitable access to cutting-edge treatments. Here, we share notable policy initiatives and examples of collaborative efforts in the United States and the United Kingdom, highlighting their goals, implementation, and potential impacts.

Continue reading

Podcast recap: Balancing privacy and progress in healthcare data with Ben Goldacre

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had an enlightening conversation with Ben Goldacre, a prominent figure in healthcare data and open science. Ben discussed his pivotal work at the Bennett Institute, highlighting projects that leverage open data to improve healthcare outcomes.

Continue reading

First-of-its-kind gene therapy restores hearing for toddler with genetic hearing loss

British toddler Opal Sandy has had her hearing restored thanks to a first-of-its-kind gene therapy. Eighteen-month-old Opal received the treatment as part of the CHORD study (sponsored by biotechnology company, Regeneron), which offers the therapy – DB-OTO – to children born with OTOF linked hearing loss. The Guardian reported last month that Opal’s parents “couldn’t really believe it,” when their daughter was able to hear for the first time after receiving the treatment.

Continue reading

Healthcare policy frameworks supporting precision medicine

Establishing robust policy frameworks to support precision medicine involves creating an ecosystem that fosters innovation, ensures safety and efficacy, and promotes equitable access. This includes addressing challenges and opportunities related to privacy, data protection, insurance, and genetic discrimination. Here, we outline the key strategies and components for setting up such programs, focusing on regulatory frameworks, data infrastructure, funding, ethical considerations, and collaborative ecosystems.

Continue reading

Webinar recap: Patient-centric product design in clinical trial technology

In the recent webinar hosted by Jess Burrows, Product Designer at Sano Genetics, and Marisa Ngbemeneh, Product Manager at Sano Genetics, we took a deep dive into the importance of patient-centric design in healthcare. The conversation highlighted how prioritising the patient experience can significantly improve clinical trials and research initiatives. 

Continue reading

Driving innovation: The role of policy in precision medicine

Precision medicine is transforming healthcare by tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. Our latest whitepaper, "From policy to practise: Integrating precision medicine into healthcare systems," highlights how effective policies can make this a reality.

Continue reading

Podcast recap: Pioneering tRNA therapies with Michelle Werner

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had a fascinating conversation with Michelle Werner, CEO of Alltrna and CEO/Partner at Flagship Pioneering. Michelle and her team are pushing the boundaries of tRNA therapies, aiming to provide scalable treatment options for people with rare and ultra-rare diseases.

Continue reading

Implementing genomics: Key strategies for early detection in at-risk populations

To fully harness the potential of genomics for early detection and prevention in at-risk populations, a comprehensive and strategic approach is crucial. Below, we outline key strategies to leverage genetic discoveries for driving early detection and prevention, particularly in vulnerable groups. The ultimate goal? To improve health outcomes and alleviate the burden on healthcare systems.

Continue reading

Exploring the future of genomics in healthcare: Early detection and prevention strategies for at-risk populations

Genomics has come a long way since the first human genome was sequenced in 2003. Today, sequencing a genome is not only faster but also significantly more affordable, thanks to advancements from industry leaders like Illumina and Oxford Nanopore. This progress has opened new avenues for research and precision medicine, particularly in identifying and supporting at-risk populations.

Continue reading

The Genetics Podcast recap: Exploring the microbiome's influence on personalised medicine with Almut Heinken

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had the pleasure of speaking with Almut Heinken, a junior professor at the INSERM Institute of Nutrition, Genetics, Environment, and Risk Exposure at Université de Lorraine. Almut’s fascinating research sits at the intersection of the microbiome, human genetics, drug discovery, and pharmacogenomics.

Continue reading

Webinar recap: Alpha-1 Antitrypsin Deficiency engagement, screening, and retention

In this webinar, "Alpha-1 Antitrypsin Deficiency: Engagement, screening, and retention," Sano Senior Project Manager, Hayley Holt, shares a case study on our work with an industry-leading sponsor to deliver genetically-qualified volunteers for a precision medicine clinical trial focused on Alpha-1 Antitrypsin Deficiency (AATD). The webinar explores the methodologies used and describes the success of the project.

Continue reading

The Genetics Podcast recap: Championing diversity and accessibility in genomics with Mavis Machirori

In the latest episode of the Genetics Podcast, Sano CEO Patrick Short had the pleasure of speaking with Mavis Machirori, a senior researcher at the Ada Lovelace Institute and co-founder of Genetics Engage

Continue reading

Navigating FDA guidance on natural history studies

Developing treatments for rare diseases involves unique obstacles due to the rarity and complexity of these conditions. To address these challenges, the FDA offers guidance on conducting natural history studies. These studies are essential for comprehending disease progression, identifying patient subgroups, discovering biomarkers, and refining clinical outcome assessments – all of which enhance the effectiveness and design of clinical trials.

Continue reading

Passion and purpose: Celebrating Clinical Trials Day at Sano

In honour of Clinical Trials Day, we're sharing some reflections from our team at Sano about why we do what we do. Clinical Trials Day marks the anniversary of James Lind's first controlled clinical trial in 1747, a key moment in medical history. For us at Sano, it’s a chance to celebrate the work we’re passionate about and the incredible people who make it possible. These quotes reflect some of our personal journeys and the reasons why we’re dedicated to advancing precision medicine. From living with genetic conditions to striving for groundbreaking discoveries, our team’s stories show the heart and commitment behind our mission to transform healthcare.

Continue reading

Understanding disease progression: The power of natural history studies

Natural history studies are essential for advancing our understanding of diseases, especially rare conditions with limited research. These studies monitor disease progression in their natural, untreated forms, providing invaluable insights that inform the development of effective treatments and precision medicine.

Continue reading

Exploring natural history studies in drug development

Natural history studies are vital for understanding disease progression, particularly in rare diseases. They provide a baseline to evaluate the effectiveness of new treatments. Our latest whitepaper explores the benefits and challenges associated with these studies.

Continue reading

Legal landscapes in precision medicine: Market access and intellectual property law [webinar recap]

This webinar is the second in a series on the complex legal environment of precision medicine, featuring Mina Frost, General Counsel for Sano Genetics. In this episode, Mina focuses on issues like market access, reimbursement, and intellectual property. Mina provides a clear breakdown of these topics, helping us understand how laws affect the delivery of innovative medical treatments.

Continue reading

Key takeaways from the World Orphan Drug Congress

Last week, our team had the opportunity to attend the World Orphan Drug Congress in Boston. The event was a dynamic gathering, where leaders from biopharma, regulatory agencies, and patient advocacy groups came together to discuss the challenges and advancements in treating rare diseases. 

Continue reading

The promising horizon of newborn genome sequencing [whitepaper]

Newborn genome sequencing represents a major shift in paediatric healthcare, offering the potential for early detection of genetic disorders and setting the stage for personalised treatment strategies from the very beginning of life.

Continue reading

From genome to bedside: Dr. Andrea Gropman on how genetics is transforming modern medical practice

In the informative webinar hosted by Dr. Patrick Short, Co-founder and CEO of Sano Genetics, guest Dr. Andrea Gropman explored the profound impact of genetics and genomics on modern medical practice. The discussion provided valuable insights into the journey of translating genetic discoveries from the laboratory to the bedside, particularly focusing on neurogenetics and metabolic disorders.

Continue reading

Patient-centric innovation: Sano's highlights from the CMO Summit 360°

Last week, Sano had the privilege of travelling to Boston for the Chief Medical Officer Summit 360°, where our Co-founder and COO, Charlotte Guzzo, shared her expertise on a panel focused on practical approaches to patient engagement. This event provided a platform for rich discussions on the shifting paradigms of drug development and precision medicine. Here, we’ll share an overview of key discussions and insights from the conference, emphasising the innovative strategies highlighted during the panels.

Continue reading

Predictive models from natural history studies in precision medicine

Natural history studies are instrumental in advancing precision medicine by offering a nuanced understanding of the patient journey across various diseases, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Huntington's Disease. This blog post explores the crucial role these studies play in disease modelling and the development of precisely targeted treatments within the realm of precision medicine.

Continue reading

Webinar recap: Understanding complex disease biology – Insights into the genetics of long COVID

This webinar, co-hosted by Sano Genetics and PrecisionLife, highlighted the complex nature of long Covid, which affects up to 30% of Covid-19 survivors and presents with more than 50 symptoms. The discussion brought to light the limitations of traditional genomic research, which has struggled to identify significant genetic risk factors, and underscored the necessity for innovative methodologies in understanding and treating this condition.

Continue reading

World Liver Day spotlight: Pioneering genetic solutions for liver disease

Liver disease remains one of the leading causes of morbidity and mortality worldwide, presenting complex challenges in healthcare due to its multifaceted nature and often silent progression. Advancements in genetic research have begun to illuminate the pathways through which liver diseases develop, revealing that conditions like metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), are not only influenced by lifestyle but also by genetic predispositions.

Continue reading

How we're safeguarding privacy in the pursuit of personalised medicine

At Sano, our mission to accelerate the world’s transition to personalised medicine hinges on precise, individualised insights from vast amounts of health data. Understanding the sensitive nature of this data, we've committed to the highest standards of privacy and data protection, as detailed in our latest whitepaper, "Sano’s privacy promise." 

Continue reading

Webinar recap: Unlocking potential - How AI is shaping the drug development pipeline

This webinar focused on the potential of artificial intelligence (AI) in drug development, particularly within the realms of precision medicine. Hosted by Charlotte Guzzo, COO of Sano, the session featured insights from top industry experts who discussed their personal journeys at the intersection of technology and healthcare, the challenges of integrating AI into drug development, and the cutting-edge innovations their companies are pioneering.

Continue reading

How natural history studies support data-driven precision medicine

Natural history studies play a pivotal role in deepening our understanding of diseases by observing them in their unmodified state. These studies offer invaluable insights by serving as "natural" comparisons for assessing the impact of treatments, thus playing a crucial role during the drug development process and in comprehending how diseases evolve without medical intervention. They act as fundamental benchmarks to gauge the effectiveness of new therapies.

Continue reading

Webinar recap: Sano product spotlight

In this webinar, Sano’s Senior Project Manager Clare Clarke shares the approach Sano employs to achieve its mission of accelerating the world’s transition to precision medicine. She outlines the seamless integration of recruitment, biomarker testing, and engagement within research trials, and provides an overview of Sano’s technology. This is the first in a series of webinars that will showcase various aspects of Sano’s product.

Continue reading

Preventive measures: The untapped potential of genomic screening

In recent years, the advent of population genomic screening has emerged as a promising approach to combat prevalent diseases such as cancer and heart disease. Population genetic screening tests a large population of otherwise healthy individuals to find genomic variants that might predispose them to diseases that are clinically actionable, meaning that they can be prevented or mitigated if they are detected early. By identifying individuals at risk of preventable and treatable conditions, this screening method has the potential to significantly reduce morbidity and mortality rates.

Continue reading

Webinar recap: Parkinson's disease engagement, screening, and retention

In this webinar, “Parkinson's disease: Engagement, screening, and retention," Sano CEO and Co-Founder Patrick Short shares a case study of Sano’s work on a genetic Parkinson’s disease clinical trial. He explores the methodologies used for this cutting-edge program, and describes the success of the project.

Continue reading

Modern medicine reimagined: Precision medicine in medical practice [whitepaper]

Our latest whitepaper, "Bridging Genes and Medicine: How genetics is redefining healthcare," examines how the adoption of genetic information is changing clinical practice by requiring a more personalised approach to healthcare. It highlights the importance of this shift, both for improving patient outcomes and for the efficiency of healthcare delivery, painting a picture of a future where treatments are as unique as the patients themselves.

Continue reading

Equity in newborn screening: A global health challenge

Over the last two decades, following the landmark achievement of sequencing the first complete human genome, a suite of powerful genetic tools has emerged. Gene panel testing, whole exome sequencing, and whole genome sequencing are now pivotal in gathering detailed genetic information. The integration of these tools into neonatal care holds the potential for helpful genetic insight from the moment of birth.

Continue reading

Engineering the future: The intersection of TERM and precision medicine in modern healthcare

Tissue engineering and regenerative medicine (TERM), integral to the evolution of precision medicine, are making strides in regenerating or repairing damaged tissues and organs. Tissue engineering uses cells, scaffolds, and growth factors to regenerate or replace damaged or diseased tissues, while regenerative medicine combines tissue engineering with other treatments like gene therapy, immunomodulation and cell-based therapy to induce tissue regeneration within the body. When combined with precision medicine's tailored approach, TERM holds immense promise for addressing some of the biggest modern healthcare issues, such as the urgent demand for organ replacements amidst an ageing population

Continue reading

Webinar recap: Genetic essentials for clinical research professionals, Part 2

Last year, Sano CEO Dr. Patrick Short presented a webinar called “Genetics Essentials for Clinical Research professionals.” In it, he explained the fundamentals of genetics in clinical research, explored the trends propelling genetics in drug development, and shared practical applications in drug discovery, development, and delivery. Now, we’re back with part 2, which goes beyond fundamentals and is presented by Sano COO Charlotte Guzzo.

Continue reading

Early insights, lifelong impact: The role of genomic screening in prenatal and neonatal healthcare

Genomic screening is transforming prenatal and neonatal care, offering new insights and challenges in equal measure. Our latest report, "Precision from the start: Balancing progress and principles in prenatal and neonatal care," dives into these advancements and the ethical dilemmas they present.

Continue reading

Webinar recap: Clinical, social, and ethical perspectives on newborn genome sequencing

This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Wendy Chung, Dr. Holly Peay, and Kira Dineen, offered a deep dive into the latest advancements in newborn screening, showcasing how cutting-edge genetic technologies are paving the way for a new era in medical care for our youngest patients. The link to the full webinar is here; a brief summary is below for easy reference.

Continue reading

The after effects: Investigating the role of immunogenetics in long COVID

The global battle against COVID-19 has shifted focus from acute infections to the lingering challenge posed by long COVID, a condition where signs and symptoms persist well beyond the initial infection. While most individuals experience a mild reaction to the virus, approximately 10% develop hypoxemic pneumonia, 3% progress to critical illness, and 28% go on to experience Long COVID.

Continue reading

The principle of precision: Why navigating the nuances in genetic test interpretation is more important than ever

Genetic testing offers a powerful lens through which we can understand and address a wide array of medical conditions, ranging from neurocognitive disorders in children to various cancers in adults. However, the rapid evolution of genomic technologies and the increasing demand for genetic testing bring to the forefront the complexities involved in interpreting genetic results. This issue is becoming increasingly pertinent for both healthcare providers and patients.

Continue reading

Webinar recap: Legal landscapes in precision medicine

This webinar featuring Mina Frost, General Counsel for Sano Genetics, provides an insightful overview of the legal and ethical intricacies involved in precision medicine. Mina expertly explores the complexities of patient privacy, data protection, and the regulatory landscape that govern precision medicine.

Continue reading

Patient centricity in focus: Insights from the 16th Annual Recruitment and Retention Summit

Recently, our team had the pleasure of attending the 16th Annual Patient Recruitment and Retention Summit, a hallmark event in the field of clinical research and patient advocacy. Hosted in an intimate, knowledge-sharing environment, this summit brought together experts from across the globe to share insights, strategies, and innovations aimed at enhancing patient involvement in clinical research. We were proud to sponsor a booth, which served as a hub for discussions, networking, and sharing our contributions to the field. In this blog, we’ll share the themes that rose to the top in our discussions. 

Continue reading

Innovation on Rare Disease Day: Recode CMO John Matthews on changing the future of genetic medicine [podcast]

In observance of Rare Disease Day, our latest episode of the Genetics Podcast presents a fascinating conversation with John Matthews, who was recently promoted to Chief Medical Officer at ReCode Therapeutics. This special episode not only commemorates the day dedicated to raising awareness for rare diseases but also showcases the innovative strides being made in the field of genetic medicine for the diagnosis and treatment of rare diseases.

Continue reading

The essential role of patient empowerment in precision medicine [whitepaper]

In our latest whitepaper, "Beyond the bench: The role of patient empowerment in shaping precision medicine research," we examine how patient involvement is transforming the field of genomics- and biomarker-driven research. In highlighting the shift towards patient-centric models, we emphasise the importance of including patient insights in the development of new treatments.

Continue reading

Systemic shifts: Steering precision medicine towards success

In today's digital age, scientists and medical professionals are harnessing the power of healthcare data to unravel the genetic foundations of various diseases. But despite the growing portfolio of precision medicines, their integration into healthcare systems is not without its hurdles. This blog explores the challenges and opportunities of integrating precision medicine into healthcare systems. 

Continue reading

Navigating the data deluge in genomics [report]

In the ever-evolving world of healthcare and scientific research, the rapid growth of genomic data stands out as both a remarkable achievement and a formidable challenge. Our new report, "Scaling genomic data: Addressing the storage, analysis, and accessibility hurdles of large-scale genomic data," sheds light on the complexities of managing this vast ocean of information that holds the key to unlocking the future of personalised medicine.

Continue reading

The precision medicine technology access challenge

In the age of advanced medical treatments, achieving health equity—in which every individual has the chance to attain their highest level of health regardless of background—is a fundamental yet unmet goal. Despite good intentions, healthcare systems globally face significant challenges in providing equal access and quality of care to all communities.

Continue reading

The newest advances in Parkinson's research

With Parkinson's disease affecting millions worldwide, the need for enhanced research is both critical and immediate to improve patient outcomes and quality of life. Here, we showcase a curated selection of recent advancements in Parkinson's research. 

Continue reading

Innovation, collaboration, and competition: Highlights from PMWC 2024

We recently had the privilege of hosting a booth and speaking in the Precision Medicine World Conference (PMWC) 2024, an event that stands at the intersection of technology, medicine, and research. This gathering of the minds is where the future of healthcare is debated, shaped, and set into motion. Our team returned invigorated by the discussions, collaborations, and insights that PMWC fostered, reflecting a shared ambition to redefine the boundaries of personalised medicine. In this recap, we share three pivotal insights that resonated with us and will continue to shape our vision for the future of precision medicine.

Continue reading

From data to decisions: The impact of digital solutions in clinical genetics

In the realm of clinical genetics, the surge in digital health technology adoption has been remarkable. These innovations, ranging from chatbots assisting with patient admissions to sophisticated machine learning algorithms enhancing genomic analysis and reporting, are revolutionising the delivery of genetic services. They are not only streamlining operations but also ensuring consistent access to healthcare. The abundance of data and the advancement of precision medicine necessitate a digital approach to healthcare interactions, fostering broader access and more tailored care.

Continue reading

Genomics and patient care: Evolving roles and scopes of practice for healthcare professionals

In the rapidly advancing realm of precision medicine, healthcare professionals (HCPs) are witnessing a transformative shift in their roles. This approach, which tailors treatment to the individual's genetic makeup, lifestyle, and environment, demands a new set of skills and knowledge from HCPs – including physicians, nurses, and pharmacists. They are now at the forefront of integrating complex genetic information into patient care, navigating ethical dilemmas, and maintaining an up-to-date understanding of technological innovations. This blog post explores how precision medicine is reshaping the responsibilities and expertise of HCPs, and what this means for patient care.

Continue reading

Sano Genetics raises $11.4 million led by Plural to power precision medicine revolution with seamless trials

  • Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement
  • Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade
  • Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies 
  • New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes 

 

Continue reading

Synergy in science: How collaboration is redefining the landscape of precision medicine


In the realm of healthcare, a pivotal shift is taking place: the growing collaboration between academia, biotechnology, and pharmaceutical industries in the field of precision medicine. This evolving partnership is more than a trend; it's transforming how we approach the development of new drugs and treatments.

Continue reading

New frontiers in rare disease research

In the ever-evolving field of rare disease research, it's crucial to remain informed about the latest progress. At Sano, our commitment is to stay ahead of these developments. We are excited to offer a curated overview of some of the most significant advancements in rare disease research from the past few months.

Continue reading

Decoding health: How AI transforms genomic medicine

In the rapidly evolving world of healthcare, a profound transformation is taking place at the intersection of Artificial Intelligence (AI) and genomics. This convergence is not just a fleeting trend; it's a fundamental shift in how we approach medicine, diagnosis, and treatment. Our latest whitepaper explores this significant development, shedding light on how AI is unlocking new possibilities in genomic medicine.

Continue reading

Taking charge: How precision medicine is transforming patient engagement

Since the advent of precision medicine, there has been a noticeable shift in patient engagement and decision-making in healthcare. Patients are now more vocal and proactive, expressing a strong desire to be actively involved in their healthcare journey. This engagement reflects an increased awareness and understanding of their health needs and options, aligning with the personalised nature of precision medicine. In this blog, we examine precision medicine’s role in empowering patients to be more involved in their healthcare decisions, then explore how this shift is shaping the dynamics between healthcare providers and their patients.

Continue reading

Key strategies for patient-centric communication in precision medicine: An essential checklist

In the rapidly evolving field of precision medicine, the role of patient engagement and communication is pivotal. As we venture into this new era of personalised healthcare, it's essential for pharmaceutical and biotech companies to establish trust and transparency with patients. This checklist serves as a guide to ensure companies are taking the right steps to effectively engage and communicate with patients participating in precision medicine research.

Continue reading

From observation to innovation: Natural history studies in the era of AI

Natural history studies play a pivotal role in advancing our knowledge of diseases. These observational studies, which track the progression of diseases in their natural state without medical intervention, are particularly crucial in the realm of rare disease research. They serve as fundamental benchmarks against which the effectiveness of new treatments can be measured. In conducting these studies, extensive data is collected over an individual's lifetime, including initial diagnosis, clinical observations, and patient insights on quality of life. This rich tapestry of information provides a deep and nuanced understanding of how a disease progresses and its impact on those affected.

Continue reading

Valuable insights and expert connections: A recap of NASH-TAG

Last week, we attended the NASH-TAG conference in beautiful Park City, Utah. Against a winter wonderland backdrop, we dove deep into the latest research on metabolic associated steatohepatitis (MASH, also known as non-alcoholic steatohepatitis or NASH) and connected with leading experts in the field. Here, we’ll share some of our key learnings, underscoring the evolving landscape of liver disease research. 

Continue reading

Strategic data sharing in precision medicine: A checklist for biotech and pharma

In the ever-changing field of precision medicine, continuous evaluation of data sharing and collaboration practices is essential for biotech and pharma companies. This ongoing assessment is vital to ensure compliance with evolving regulations, protect patient privacy, and foster innovative research. Drawing from our expertise in this area, we've created a straightforward checklist to help these companies responsibly handle genetic and biomarker data and collaborate effectively with third parties.

Continue reading

Collaborative intelligence: How AI partnerships are shaping the future of drug development

The digitisation of medical records is catalysing the use of AI in various sectors of healthcare, including clinical trials, precision medicine, and drug discovery, thereby supporting biotech and pharmaceutical companies in their quest for more efficient and personalised medical solutions. This blog post explores the transformative role of AI in fostering collaborations within and beyond these industries, highlighting its impact on drug discovery and the development of personalised medicines, while also addressing the challenges and ethical considerations involved.

Continue reading

A precision medicine year in review

As the new year unfolds, it's a time for reflection on some of the most inspirational stories in human genetics last year, and anticipation of what's to come in this area in 2024.

Continue reading

The DNA divide: Exploring the importance of genomic literacy

In the two decades since the first human genome sequencing, technological progress has unlocked an enormous collection of genetic data. This invaluable resource has deepened our understanding of DNA's role in diseases and the diverse genetic makeup among individuals. However, a significant caveat exists: a disproportionate amount of this data stems from individuals of European descent. As of 2021, over 86% of genomic data hails from this group, with East Asians contributing around 6%, Africans 1%, and all other demographics less than 1%. This skew in data collection limits the potential benefits of genomic research for underrepresented populations. And one issue at the heart of it is a lack of genomic literacy. 

Continue reading

Cultivating cultural competence in genomic medicine: A key to inclusive healthcare

In today's increasingly interconnected global landscape, the ease of movement and migration has led to a significant rise in diversity within numerous countries. This diversity is characterised by distinct cultural backgrounds that considerably influence individuals' reactions to various healthcare services, including the progressively important field of genomic medicine. In this context, cultural competency becomes an essential skill for researchers and healthcare providers. It plays a pivotal role in bridging cultural differences, ensuring that high-quality care is delivered uniformly, transcending barriers of race, gender, or beliefs.

Continue reading

Towards inclusive health: Bridging genomic data and equity in healthcare

Health equity, defined as everyone having the opportunity to be as healthy as possible, has long been a primary goal of public health. Still, across the world, people don't have the same opportunities to see doctors, take part in research, or access medications and genetic testing. This disparity of care can affect rates of disease and disability – and most importantly, hinder quality and length of life. 

Continue reading

Inclusive genomics: Unlocking equitable healthcare through diversity

Our new whitepaper "Inclusive genomics: A path to equitable precision medicine" offers a close look at the intersection of genomic research and diversity. It's an exploration of how embracing the full spectrum of human diversity is not just beneficial but essential for the advancement of precision medicine.

Continue reading

Reflections from the 34th International Symposium on ALS/MND

The 34th International Symposium on ALS/MND represented a pivotal moment in the ongoing fight against Amyotrophic Lateral Sclerosis (ALS). This year's event was especially significant, commemorating the 30th anniversary of the discovery of SOD1, the first monogenic cause of ALS, and showcasing the substantial progress made in understanding the genetic components of this complex disease.

Continue reading

Introducing "Light the Way:” A new dawn in ALS care and support

As we step into a new era of medical innovation, it's crucial to shine a light on diseases that have long remained in the shadows. Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease also known as motor neuron disease (MND), is one such condition that has challenged medical experts for decades. Today, we’re thrilled to share a beacon of hope in this challenging landscape: Sano’s launch of “Light the Way.”

Continue reading

Introducing Light the Way [press release]

Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies

  • Sano Genetics launches ‘Light The Way’, offering peer support, DNA testing, genetic counseling and education to those diagnosed with or experiencing symptoms of ALS, and those at risk of genetic ALS due to their family history.
  • Around one in five ALS cases are now thought to be genetic; 40+ genes have been linked to the disease thanks to new discoveries funded in part by the 2014 ALS ice bucket challenge.*
  • Knowing their genetic risk could offer relief to many, while those who test positive may be able to access newly approved therapies, clinical trials and observational studies like Beacon, which charts the psychological impact of ALS genetic testing.

 

Continue reading

Engaging patients in precision medicine: Best practices for researchers

In the ever-evolving landscape of healthcare, precision medicine trials stand out as a beacon of personalised treatment, tailored to the unique genetic and environmental makeup of each individual. But the backbone of these trials isn't just cutting-edge technology or groundbreaking research; it's the patients. Engaging them effectively is both an art and a science. Here, we explore best practices for patient engagement in this dynamic field.

Continue reading

What are the economic implications of precision medicine?

As the interest in precision medicine grows, so does the interest in its economic implications. Economic evaluations are used to determine the value of treatments, helping policymakers allocate resources wisely. However, these evaluations can be difficult for precision medicine. In this blog post, we delve into the economics of precision medicine, exploring its cost-effectiveness and the broader economic benefits of tailored treatments.

Continue reading

ALS: Insights and innovations in treatment and research [report]

In our latest report, we explore the complexities of Amyotrophic Lateral Sclerosis (ALS), offering a comprehensive overview of the disease. From genetic components to the latest FDA-approved treatments, we cover the entire spectrum of ALS research and care.

Continue reading

A new horizon in liver disease management [whitepaper]

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a complex liver disease characterized by fat accumulation, inflammation, and fibrosis. With its global prevalence rising alongside obesity and type 2 diabetes rates, the medical community is urgently seeking innovative prediction, diagnosis, and treatment strategies.

Continue reading

Webinar recap: Bridging genomics and precision medicine

This webinar, hosted by Sano CEO Dr. Patrick Short and featuring David Ochoa, Platform Coordinator at Open Targets, explores the significance of human genetics in pinpointing drug targets, the variety of data sets employed, target safety, and methods of intervention. It also touches on the changing nature of drug modalities and prospective avenues for future research.

Continue reading

The pivotal role of genetic counselling in biotech and pharma precision medicine

The relationship between DNA and health is being understood better every day. We now know that our genes affect our risk of disease, symptoms, and even how we react to medications. But with genetic testing becoming a more prominent part of healthcare, genetic counsellors play a vital role in supporting people through the process and helping them understand the results of testing and what it means for them as patients. In this blog, we'll discuss the importance of genetic counsellors and how they bridge the gap between scientific advancement and patient care.

Continue reading

From lab to life: How genetic testing is transforming pharma and biotech

The 21st century heralds a paradigm shift in healthcare and medicine, driven predominantly by the breakthroughs in genetic testing. This blog post explores how genetic testing is redefining the fields of biotechnology and pharmaceuticals, marking a new era of precision medicine. From decoding our DNA to ushering in targeted therapies, genetic testing stands as a cornerstone of modern medical innovation.

Continue reading

Precision at scale: The role of health digital twins in the future of medicine

Digital twins are virtual models designed to accurately reflect a physical object or system. The concept comes from engineering and has been applied to complex systems such as airplanes, manufacturing, and even cities. While the use of digital twins in healthcare is still very new, it is already showing promise for more personalised treatments and creating a better understanding of patient health.

Continue reading

The genetic crystal ball: How polygenic risk scores predict disease risk and guide drug discovery

While lifestyle choices and environment can impact risk, genes are often what most affect how likely a person is to develop a disease. People commonly have different versions of a gene throughout a population, and some of these versions are associated with an increase in disease risk. Polygenic risk scores consider these gene variations and can provide a measurement of a person's risk for a specific disease.

Continue reading

Boosting clinical trial patient recruitment: The role of patient recruitment vendors and platforms

Clinical trials are the cornerstone of medical advancements, allowing researchers to develop new treatments, therapies, and medications. However, a critical challenge in conducting successful clinical trials is patient recruitment. Efficient patient recruitment ensures that trials progress smoothly, providing results that benefit both the medical community and patients. To overcome this challenge, clinical trial patient recruitment companies and platforms play a vital role. In this blog, we’ll examine the world of clinical trial patient recruitment, exploring the role of various vendors and platforms.

Continue reading

CRISPR and the future of healthcare: Promise and challenges

Clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein (Cas) systems are programmable genome editing tools that can mediate site-specific DNA modifications. Although gene-editing technologies, including CRISPR, enable highly specific treatments tailored to individuals, their clinical success depends on overcoming issues like efficiency, gene correction specificity, and precise cell targeting. Here, we'll discuss the potential gene-editing technologies like CRISPR have for personalised therapies, as well as the challenges and regulatory landscape that affect its clinical uptake.

Continue reading

Cracking the genetic code of metabolic dysfunction-associated steatohepatitis (MASH)

The development of MASH, the advanced stage of nonalcoholic fatty liver disease, is a complex interplay of genetic and environmental factors. Genes like PNPLA3, TM6SF2, GCKR, MBOAT7, and HSD17B13 play pivotal roles in MASH susceptibility. Lifestyle factors, particularly diet and exercise, amplify the genetic influence on MASH risk.

Continue reading

Pharmacogenomics: Tailoring therapies for maximum safety and efficacy

Pharmacogenomics, also known as pharmacogenetics, is a field of research dedicated to investigating how an individual's genetic makeup influences their response to medications.

Continue reading

Webinar recap: The evolving landscape of liver disease

This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Dimitar Tonev, an expert in liver disease and hepatology, sheds light on the latest developments in liver disease – particularly metabolic dysfunction-associated steatohepatitis (MASH) – including significant changes and predictions for the future.

Continue reading

Bolstering patient engagement to drive retention success

Keeping participants engaged in clinical research can be difficult. Here, we let the statistics tell the story:

Continue reading

Connecting the dots: How phenotypic data enhances genetic insights in research 

Genetic data is at the heart of precision medicine. Understanding the influence of genetics on health has helped us to recognise risk factors for disease, predict how patients might respond to treatments, and develop targeted treatments. But how does this knowledge connect to phenotypic data – the expression of the interaction between genes and the environment?

Continue reading

DPharm recap: Participant experience and incentives in focus

DPharm 2023 has come to a close, and as we reflect on the sessions and insights shared, two themes clearly stood out this year: The participant experience and incentives for participants. In this blog, we’ll dive deeper into these central areas of discussion.

Continue reading

COVID-19 and genomic sequencing: Tracking variants and lessons for future pandemics

As COVID-19 continues to affect us all, it has become evident that our fight against the virus is not just about developing vaccines and therapeutics. Equally crucial is our ability to track the virus’s mutations and adaptations. Enter genomic sequencing – a technology that has taken centre stage in our ongoing battle against the pandemic. Here, we explore how genomic sequencing has been instrumental in tracking SARS-CoV-2 variants and its implications for future pandemics.

Continue reading

Can ALS be Caught Early: Unravelling the Detection of ALS

In this blog, we're exploring whether ALS can be caught early, including the tests that may be used in order to diagnose ALS, and if there are any measures that can be put in place to stop it early. 

Continue reading

From genes to cures: How genomic data guides drug target discovery

In the constantly evolving pharmaceutical and biotech industries, the search for new drug targets is an ongoing effort. Clinical operations professionals play a pivotal role in this endeavour, and one of the most promising tools at their disposal is genetic data. In this blog, we will explore how genetic data is harnessed to identify drug targets, and what this means for the drug development process.

Continue reading

The long haul: How long COVID continues to challenge healthcare

Long COVID, affecting nearly 28% of COVID-19 survivors, is a multifaceted condition that extends well beyond its initial impact. Typical include fatigue, concentration difficulties, and shortness of breath – but researchers have identified more than 200 symptoms associated with long COVID. It remains a global health puzzle, but research is paving the way for a deeper understanding and improved treatments.

Continue reading

Omnichannel recruitment channels for clinical trials

In the ever-evolving landscape of clinical trial recruitment, an omnichannel approach is becoming increasingly crucial to ensure a diverse and engaged participant pool. This approach involves the integration of various outreach methods to reach potential participants through traditional methods, digital channels, patient advocacy groups, patient databases, and more. Each of these approaches has its pros and cons, offering unique opportunities and challenges to recruit participants effectively. Understanding these benefits and disadvantages can help researchers put together a perfectly blended omnichannel approach.

Continue reading

Handling variants of uncertain significance (VUS) in clinical trials

When a person undergoes genetic testing, they often expect to find definitive answers about their genes. However, around 20% of genetic tests identify variants of uncertain significance (VUS). These enigmatic genetic mutations often leave researchers and patients with more questions than answers. Unlike harmful mutations that may cause cancers or benign ones that aren't linked to illness, researchers lack sufficient information about VUS to determine their association with any conditions. Here, we'll outline what VUS actually are, their significance in clinical trials, and some effective strategies to manage them.

Continue reading

What is a patient registry, and what role do they play in precision medicine clinical trials?

Back in 2015, a study published in Nature suggested that by harnessing genetic data to support the selection of candidate drugs, researchers could double their success rates. Considering that only around 10% of clinical programs ultimately result in an approved drug, using genetic data can be game-changing for drug development. Patient registries serve as repositories of genetic information that can be used during precision medicine trials to help us better understand medical conditions and why people react to treatments differently. In this blog, we’ll define genetic patient registries and discuss how they support research and what to keep in mind if you're considering making use of one.

Continue reading

The science of success: Clinical trial recruitment strategies [whitepaper]

Clinical trials drive medical progress, but their success relies on effective patient recruitment. And recruiting patients for clinical trials is no small task. Consider these statistics: 37% of trial sites struggle with under-enrollment, 11% fail to enrol any patients, and 90% of trials need their timelines doubled to meet goals. Recruiting one patient costs an average of $6,533, with replacing a drop-out patient soaring to $19,533. Getting patient recruitment right is paramount.

Continue reading

The genetic evidence advantage in drug development

In the ever-evolving world of healthcare and pharmaceuticals, researchers are constantly seeking ways to make drug development more efficient and effective. Sano’s new report, “Why are drug targets with genetic evidence twice as likely to succeed in trials?” sheds light on the use of genetic evidence to significantly increase the success rates of drugs in clinical trials, offering a glimpse into the future of personalised medicine.

Continue reading

What are the major sources of genetic data for drug discovery?

Genetics plays a principal role in health and disease, and continues to become increasingly important for drug development. With genetic data, the focus is shifting from traditional trial-and-error approaches towards precision medicine. This data helps us to understand the genetic underpinnings of diseases, enabling the identification of potential drug targets and more personalised treatment strategies. In this blog, we explore the major sources of genetic data that drive advancements in drug discovery, ranging from genomic databases to cutting-edge sequencing technologies.

Continue reading

Understanding the modern genetic testing landscape

In the world of healthcare, genetics is ushering in a new era of personalised insights that are transforming how we approach healthcare. Our latest report, “The Genetic testing landscape: A look at the modern approach and the value of sponsored programs,” offers a valuable exploration of the evolving genetic testing landscape. 

Continue reading

The power of patient registries

In the fast-paced world of medical research, patient advocacy groups have emerged as powerful drivers of change. One critical ingredient in their recipe for success is patient registries. These tools offer a direct relationship between patients and researchers, propelling medical advancements and accelerating the search for better treatments. Our newly released whitepaper, titled "Connecting communities: Engaging patients in registries for long-term impact," shares strategies and insights for patient advocacy groups that want to create impactful patient registries. 

Continue reading

Webinar recap: Ethical and regulatory landscapes in precision medicine

The rapidly evolving landscape of precision medicine has opened new avenues for personalised treatments, transforming how we approach patient care. Genetic information is now pivotal in tailoring medical interventions to individual needs. However, with this innovation comes a complex web of ethical and regulatory considerations that must be carefully navigated to ensure patient safety, data privacy, and ethical conduct. Here are the key insights and lessons from a recent Sano webinar in which Sarah Howard, our Head of Quality and Regulatory, shed light on the ethical and regulatory landscapes surrounding precision medicine.

Continue reading

6 genetics podcasts you need to listen to

Are you curious about the blueprint of life that shapes everything around us? Genetics podcasts offer an easy and engaging way to explore the fascinating world of DNA, genes, and heredity. Whether you're a science enthusiast or just intrigued by how our genes work, tuning into these podcasts can be both educational and entertaining. Here are six great options:

Continue reading

7 ways you can work with Sano

In the complex world of medical research, collaboration is key to driving innovation and progress. Sano exists to accelerate the transition to precision medicine, and in the spirit of collaboration, we’ve honed our offerings to ensure value for clients based on their specific needs. Below you’ll find seven practical ways sponsors and other researchers have worked with us to achieve their goals. 

Continue reading

Navigating genetic testing regulations for clinical trials in the US, UK, and Europe

The healthcare sector is constantly changing, with cutting-edge medical equipment, life-changing drugs, and innovative procedures evolving to provide care to patients around the globe. Genetic testing has become an integral tool within the sector over the past few years, offering new ways to understand and diagnose conditions, while providing a gateway to more personalised treatment options.

Continue reading

Exploring genetics in clinical research: A comprehensive guide

Genetics is reshaping the landscape of clinical research, and our latest whitepaper, "Guide: Genetics Essentials for Clinical Research Professionals," offers a concise yet comprehensive overview of this rapidly evolving field. This guide explores genetics' crucial role in drug development, discovery, and patient care.

Continue reading

Genetics without borders: Advancing diversity in precision medicine

Precision medicine marks a shift from the one-size-fits-all approach to healthcare to tailored treatments and interventions that cater to an individual's unique genetic makeup, lifestyle, and environment. While precision medicine has the potential to improve patient outcomes and speed up clinical trials, it relies on the participation of diverse and representative populations. Diversity ensures that medical insights are applicable across a wide range of individuals, preventing biassed results that may favour specific ethnic or demographic groups.

Continue reading

Webinar recap: Opportunities in improving recruitment in decentralised clinical trials

In this webinar, Patrick Short, CEO of Sano Genetics, discussed opportunities to improve clinical trial patient recruitment in decentralised clinical trials (DCT) with Joss Warren, the Vice President of Strategic Accounts at THREAD Research. Their discussion covered how DCTs are changing the clinical research landscape, and what they mean for diversity in clinical trials as well as the future of precision medicine.

Continue reading

Multiple Sclerosis (MS) insights report: Impact, Treatment, Genetics, and Community

Our latest insights report explores multiple sclerosis (MS), providing details on the essential aspects of MS, from its impact on the central nervous system to the varying types of the condition. We share insights on:

Continue reading

Webinar recap: Genetics essentials for clinical research professionals

In this webinar, Sano co-founder and CEO Patrick Short discusses the essentials of genetics and genomics, including genetic variation, genetic testing, and more. Patrick offers a thorough overview of current discoveries and discusses how they may impact the future of clinical practice.

Continue reading

Navigating rare disease patient recruitment

Rare diseases may impact a small portion of the population, yet their significance is profound. And while rare disease patient recruitment might seem similar to recruitment for more prevalent conditions, it's a puzzle of its own. Conditions affecting a fraction of the population present complex obstacles. From the intricate challenge of participant scarcity, where the rarity of these conditions presents a unique hurdle, to the multi-faceted complexities of engagement, the world of rare disease trials demands innovative strategies that reframe the way we approach research.

Continue reading

How does genetics impact enrolment planning for clinical trials?

In recent years, it's been discovered that genetics can play a big role in developing a condition and even affect how a patient might respond to treatment. Because our genes can have such an impact on our health, genetic screening has become an important part of many clinical trials. With precision medicine research coming to the fore, how can researchers and their teams plan ahead to incorporate genetics into their enrolment planning? 

Continue reading

Hope and progress: Light the Way at the ENCALS meeting

Last month, our team had the pleasure of attending the European Network to Cure ALS (ENCALS) meeting, an annual gathering that brings together some of the brightest minds in the field of amyotrophic lateral sclerosis (ALS) research and treatment. Each year, the ENCALS meeting reaffirms the commitment of the scientific community to ending ALS and brings renewed hope to patients and their families. While our team enjoyed networking with attendees and catching up on the latest research in ALS, this year they were also focused on Sano’s poster presentation for an initiative we are calling Light the Way.

Continue reading

£330K grant awarded to support and engage patients at risk of MND/ALS

£330K grant awarded to support and engage patients at risk of MND/ALS, and track the psychological impact of genetic testing.

Continue reading

Connecting for success: The power of purposeful participant engagement

This webinar, featuring Sano Genetics team members Ross Rounsevell and George Bowley, highlights the importance of purposeful participant engagement in research studies. The discussion centres around meaningful research participant engagement, its significance in research, strategies for effective engagement, and the future developments enabling better study design. 

Continue reading

AATD insights report: Exploring impact, challenges, and genetic components

Our latest insights report focuses on Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder with significant implications for lung and liver health. AATD arises from a deficiency of the alpha-1 antitrypsin protein, which safeguards the lungs from damage. However, with this protein in short supply, the lungs become susceptible to inflammation, potentially leading to conditions like emphysema and chronic obstructive pulmonary disease (COPD).

Continue reading

Webinar recap: International perspectives on genetic testing in ALS

This webinar, hosted by Paul Wicks and featuring a panel of experts in ALS and genetics, focuses on the challenges and variability in genetic testing and counselling for ALS. The experts highlight that while genetic testing is a critical component of ALS research and treatment, key challenges include making the test available to everyone who needs it and ensuring consistency among tests.

Continue reading

A dozen powerful allies in clinical trial design and protocol development

The process of clinical trial design and protocol development is a multifaceted and often complex task, demanding an intricate understanding of various elements – from disease pathology and drug characteristics to patient demographics. Add the challenge of integrating genetic research and prioritising patient engagement, and it becomes a sophisticated puzzle. However, such complexity is the engine that drives the evolution of precision medicine. Today, we explore twelve companies shaping the landscape of precision medicine by applying unique approaches to overcome design and protocol development challenges.

Continue reading

Webinar recap: Does the age of onset in SOD1-mediated ALS affect the speed of progression?

In this webinar, Dr. Sarah Opie-Martin and Dr. Paul Wicks discuss the latest research on SOD1 gene variants and their association with ALS. The webinar explores the implications of these findings for the diagnosis and treatment of ALS, and discusses potential avenues for future research.

Continue reading

Navigating smooth clinical trials: Tips for pharma and biotech sponsors to avoid study rescue

Clinical trials play a crucial role in the development of pharmaceutical and biotech products. However, unforeseen challenges can arise during the trial process, potentially jeopardising the integrity and outcomes of the study. As a recent Applied Clinical Trial article noted, “while drug discovery is mostly about science, drug development is rich with, and risked by, human drama.”

Continue reading

Data security and privacy considerations for the biotech industry

Data security and privacy are critical considerations in the biotech industry, especially for companies working in genetics.

Continue reading

Webinar recap: Why patient centricity is no longer optional in ALS clinical trials

Patient centricity has become increasingly important in clinical trials for ALS. In this webinar, host Paul Wicks and Cathy Collet discuss the challenges of patient engagement in ALS clinical trials and the potential ways to overcome them.

Continue reading

Unravelling the complexities of genomics-driven drug discovery [whitepaper]

Genomics-based drug discovery offers great potential for the development of targeted therapies that can offer new and better treatment options for patients. By utilising genetic and biomarker information, this approach allows us to gain insights into the fundamental causes of diseases. But this growing field is not without its challenges.

Continue reading

Reflections from EASL: Genetic insights, potential treatments, and nomenclature transformations in liver disease

Last week, our team had the privilege of attending the European Association for the Study of the Liver (EASL) conference, where groundbreaking advancements in liver research were unveiled. The conference provided an exceptional platform for experts and researchers to exchange knowledge and foster collaboration in the field of liver disease. In discussions with fellow conference-goers, our team identified several noteworthy themes emerging as key areas of interest. These included the pivotal role of genetics, particularly the PNPLA3 gene, in driving liver fibrosis in NAFLD/MASLD, the significance of AATD SERPINA 1 - PiZZ genotype pathogenicity, and the nomenclature change in NASH and MASH. Here, we will explore these developments, shedding light on the implications they hold for the future of liver disease research and patient care.

Continue reading

Measuring and optimising clinical trials based on data: How to harness data for success

At Sano, we know that measuring and optimising data is the key to successful execution of clinical trials. That’s why we’ve put together a three-page report on key strategies to measure and optimise your data in a way that streamlines your operations. In it, we explore the significance of data collection and integration, real-time analytics, performance metrics, and predictive modelling in the world of clinical trials. Download below to learn more!

Continue reading

Webinar recap: The Genetics of MASLD & MASH

This webinar, hosted by Lindsey Wahlstrom-Edwards, Partnerships Lead for Sano Genetics, and featuring Wayne Eskridge and Dr. Neeraj Mistry from the Fatty Liver Foundation, was an informative session on the genetics and lifestyle factors that contribute to metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Continue reading

Webinar recap: Genetic Testing 201: Considerations and next steps for sharing your results

This webinar, moderated by Patrick Short, CEO and co-founder of Sano Genetics, and featuring two panelists, Jessi Keavney and Krista Qualmann, discussed the importance of genetic testing in understanding an individual's risk for Parkinson's disease.

Continue reading

The value of patient engagement in clinical trials

Patient engagement has always been a cornerstone of successful clinical trials. It's a dynamic process that begins long before the trial and continues well after its conclusion. By fostering a strong relationship between researchers and patients, patient engagement can help improve enrollment, boost retention rates, improve the accuracy of data collected, and ensure the trial's overall success. This blog outlines the importance of patient engagement, then introduces the concept of a “Virtual Waiting Room” through which clinical trial sponsors can engage patients throughout the stages and phases of a study.

Continue reading

10 companies to support your clinical trial e-consent needs

In the rapidly evolving landscape of clinical trials, technology continues to reshape and optimise various aspects of the research process. One area where digital innovation has made significant strides is in the realm of electronic consent, or e-consent. This approach to obtaining participant consent leverages the power of digital platforms to streamline and enhance the enrollment experience. By eliminating cumbersome paper-based processes, e-consent makes the consent process more efficient, accessible, and user-friendly. Participants can conveniently review and provide consent remotely, overcoming geographical barriers and expanding the reach of clinical trials. Additionally, interactive features and multimedia elements incorporated in e-consent platforms foster better participant comprehension, empowering individuals to make informed decisions about their participation. 

Continue reading

The promising power and ethical considerations of newborn sequencing (inspired by the World Orphan Drug Congress USA)

Recently, our team was honoured to attend the World Orphan Drug Congress USA in Boston. The event brought together key stakeholders, experts, and industry leaders in the field of orphan drugs and rare diseases, and provided a platform for collaboration, knowledge sharing, and innovation in the pursuit of improved treatments for rare diseases. The Sano team enjoyed the insightful keynote presentations, interactive panel discussions, and valuable networking opportunities. 

Continue reading

Pioneering progress: The history of women in clinical trials

Clinical trials are crucial for advancing medical knowledge, developing life-saving treatments, and improving healthcare outcomes. However, for much of history, the participation of women in clinical trials has been limited or non-existent. In this blog, we explore the history of women's inclusion in clinical trials, highlighting the challenges faced and the progress made over time.

Continue reading

The future of clinical trials: Exploring key trends shaping research

As the landscape of healthcare and technology continues to evolve, clinical trials are undergoing significant transformations. In our latest trend report, we delve into the future of clinical trials, highlighting key trends that are revolutionising the research process. From collaboration and transparency to decentralised trials and patient-centred research, these trends hold the promise of a more efficient, inclusive, and patient-centric approach to medical advancements.

Continue reading

Unlocking the power of DNA Testing for Parkinson's disease: A comprehensive guide

Parkinson's disease (PD) is a rapidly growing neurodegenerative disorder affecting millions worldwide. As research progresses, we are learning more about the role of genetics in PD development. DNA testing has emerged as a powerful tool for identifying genetic mutations associated with an increased risk of Parkinson's disease.

Continue reading

Promoting diversity in clinical trials: Easy ways to drive positive change

Clinical trials play a vital role in advancing medical research, developing innovative treatments and improving patient care. But, a major challenge persists in the field: a lack of diversity among participants.

Continue reading

Selecting the right lab for clinical trial DNA sequencing

DNA sequencing can play an important role in clinical trials, providing valuable insights into genetic variations and facilitating research in personalised medicine. However, choosing the right laboratory for DNA sequencing is crucial to ensuring precise results. In this blog post, we will discuss the key factors to consider when selecting a lab for clinical trial DNA sequencing, including expertise, technology, quality control, turnaround time, and data security.

Continue reading

Why your clinical trial patient recruitment strategy should include EMR retrieval

In the ever-changing landscape of clinical trials, patient recruitment remains an ongoing challenge. To overcome this, researchers and sponsors are increasingly turning to innovative methods, such as electronic medical record (EMR) retrieval. Using EMR data effectively, clinical trial teams can enhance their recruitment strategies and improve overall trial success. Here, we explore how and why EMR retrieval can transform your patient recruitment approach. 

Continue reading

Nuances in the clinical trial market: EU vs. US

Clinical trials are vital for advancing medical knowledge and improving patient care. However, conducting trials in different regions, such as the European Union (EU) and the United States (US), involves navigating unique regulatory frameworks and cultural factors. In this blog post, we will explore the nuances in the EU and US clinical trial markets, focusing on study design and protocol development, patient recruitment, prescreening, consent, and patient engagement.

Continue reading

How to select the right patient registry for your clinical trial

Patient registries, sometimes called patient databases, are a useful tool in any clinical trial patient recruitment strategy. They help researchers quickly identify potential study participants who may meet trial eligibility requirements and have raised their hand as interested in participating in research. In addition, they assist with ensuring that the patient pool is representative of the population being studied. With so many registries available, it can be challenging to know which one might work best for your particular study. Here, we discuss some key factors to consider when selecting a patient registry for clinical trial patient recruitment.

Continue reading

What to consider when using different channels for Parkinson's recruitment

Clinical trials play a critical role in developing new treatments and therapies for Parkinson's disease, an age-related degenerative brain condition that causes slowed movements, tremors, balance problems, and more. Parkinson's disease affects more than 10 million people worldwide, and its prevalence is expected to continue to rise as the population ages. However, with some treatment options currently approved and many trials looking for newly diagnosed or treatment-naive patients, recruiting patients for these trials can be quite challenging. Using a variety of different recruitment channels can help reach the right patients, where they are and when they are looking for options. Here are some important factors to consider when selecting different channels for Parkinson's disease clinical trial patient recruitment.

Continue reading

Webinar recap: Representation Matters: Why equitable access & community engagement are critical in genetic research

This webinar, hosted by Sano Genetics Partnership Lead Lindsey Wahlstrom-Edwards and featuring representatives from COUCH Health, Lupus Research Alliance, and Acclinate, highlighted the importance of equitable access as well as community and patient engagement in precision medicine. The discussion centered on various user research topics and methods, including how to evaluate user feedback effectively and the importance of understanding user needs.

Continue reading

How to pick the right CRO for your trial

For clinical trial sponsors, selecting the right Contract Research Organization (CRO) is a critical piece to the successful execution of a clinical trial. CROs can assist with a wide variety of important elements of the research process, including feasibility and study design, executing the protocol, managing data, and providing regulatory support. It’s important to choose a CRO that understands the services you are and are not looking for, and can work towards meeting your study objectives. In this blog, we’ll review some key considerations to take into account when bringing on a CRO, including CRO focus, services offered, and questions to ask.

Continue reading

Podcast recap: Lessons from the world's largest genomic datasets

In this episode of "The Genetics Podcast," host Patrick Short interviews Daniel McArthur, Director of the Centre for Population Genomics at the Garvan Institute of Medical Research and the Murdoch Children's Research Institute. The discussion focused on the impact of large-scale genetic datasets on patient diagnosis and treating genetic subtypes of disease, and the power of big data and consortiums to enable pioneering discoveries.

Continue reading

Combining machine learning with genetic and medical data in UC

Sano Genetics and BenevolentAI have successfully completed the first phase of their research collaboration. 

Sano and BenevolentAI have worked closely over the past year to generate a linked genetic and medical record dataset for patients with ulcerative colitis (UC). The project, partly funded by the UK government’s innovation agency grant, uses a study design that doesn’t require patients to travel to specific clinical sites, thus placing them at the heart of the process, enabling ‘real-world’ data to be collected, and creating more interactions between patients and researchers.

Continue reading

Webinar recap: How can applying a "rare disease mindset" accelerate and de-risk precision medicine trials?

In a this webinar, Patrick Short, CEO and co-founder of Sano Genetics, and Patti Engel, CEO of Engage Health, discussed how applying a “rare disease mindset” can accelerate and de-risk precision medicine research. The discussion focused on a case study of a precision medicine trial in movement disorders, particularly Parkinson's disease, where they successfully identified patients with rare genetic variants of interest.

Continue reading

Challenges with relying on site databases and patient recruitment companies

Recruiting patients for clinical trials is a crucial component of the drug development process, and a key factor in determining the success or failure of a study. However, finding the right patients is challenging, and many trial sponsors and clinical research organisations (CROs) turn to clinical trial patient recruitment companies and site databases to help identify and enrol suitable candidates. Of course, these resources can be helpful, but for certain types of trials, there are challenges associated with relying on them. In particular, trials looking for patients with particular biomarkers may be too specific to rely on a traditional patient recruitment company or a site database. In this blog, we review these challenges and alternative methods which may address them.

Continue reading

For DNA Day, 5 DNA testing solutions for clinical research

National DNA Day, observed on April 25th, commemorates the discovery of the double helix structure of DNA. It’s an annual, global celebration – and this year, it marks both the 20th anniversary of the Human Genome Project’s completion and the 70th anniversary of the discovery of the DNA double helix. National DNA Day is a day to reflect on the importance of genetics and DNA research in our lives, including the impact it has had on healthcare. 

Continue reading

CMO Summit 360: Reflections on understanding patient populations, the role of advocacy, and diversity in medical research

Earlier this month, our team had the pleasure of attending the CMO Summit 360 in Boston. This event brought together top-level medical executives and experts from the biotech industry to discuss the latest trends and innovations in clinical decision making, regulatory strategy, communications, business development, and more. Sano sponsored a table at the event, and was excited to chat with and learn from both attendees and speakers. In this blog, we outline three key themes that emerged throughout the event: understanding the patient, engaging patient advocacy groups (PAGs), and driving diversity in medical research.

Continue reading

Sano's solutions to drive precision medicine forward

If you’re struggling to enroll your trial, you’re not alone. It’s so difficult that nine out of ten trials require the original timeline to be doubled to meet enrollment goals – and when you add in a genetic component, it becomes even more challenging.

Continue reading